Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia

PURPOSE: Tamoxifen administered for 5 years at 20 mg/d is effective in breast cancer treatment and prevention, but toxicity has limited its broad use. Biomarker trials showed that 5 mg/d is not inferior to 20 mg/d in decreasing breast cancer proliferation. We hypothesized that a lower dose given for...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: DeCensi, Andrea, Puntoni, Matteo, Guerrieri-Gonzaga, Aliana, Caviglia, Silvia, Avino, Franca, Cortesi, Laura, Taverniti, Cristiana, Pacquola, Maria Grazia, Falcini, Fabio, Gulisano, Marcella, Digennaro, Maria, Cariello, Anna, Cagossi, Katia, Pinotti, Graziella, Lazzeroni, Matteo, Serrano, Davide, Branchi, Daniela, Campora, Sara, Petrera, Marilena, Buttiron Webber, Tania, Boni, Luca, Bonanni, Bernardo
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2019
Soggetti:
Original Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6601429/
https://ncbi.nlm.nih.gov/pubmed/30973790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.01779
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi